The Role of Simultaneous Integrated Boost in Locally Advanced Rectal Cancer Patients with Positive Lateral Pelvic Lymph Nodes.

chemoradiotherapy lateral pelvic positive nodes locally advanced rectal cancer radiotherapy simultaneous integrated boost

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
24 Mar 2022
Historique:
received: 15 01 2022
revised: 04 03 2022
accepted: 15 03 2022
entrez: 12 4 2022
pubmed: 13 4 2022
medline: 13 4 2022
Statut: epublish

Résumé

Aims: Between 11 to 14% of patients with locally advanced rectal cancer (LARC) have positive lateral pelvic lymph nodes (LPLN) at diagnosis, related to a worse prognosis with a 5-year survival rate between 30 to 40%. The best treatment choice for this group of patients is still a challenge. The optimal radiotherapy (RT) dose for LPLN patients has been investigated. Methods: We retrospectively collected data from LARC patients with LPLN at the primary staging MRI, treated in our center from March 2003 to December 2020. Patients underwent a neoadjuvant concomitant chemo-radiotherapy (CRT) treatment on the primary tumor (T), mesorectum, and pelvic nodes, associated with a fluoride-based chemotherapy. The total reached dose was 45 Gy at 1.8 Gy/fr on the elective sites and 55 Gy at 2.2 Gy/fr on the disease and mesorectum. Patients were divided in two groups based on whether they received a simultaneous integrated RT boost on the LPLN or not. Overall Survival (OS), Disease Free Survival (DFS), Metastasis Free Survival (MFS), and Local Control (LC) were evaluated in the whole group and then compared between the two groups. Results: A total of 176 patients were evaluated: 82 were included in the RT boost group and 94 in the non-RT boost group. The median follow-up period was 57.8 months. All the clinical endpoint (OS, DFS, MFS, LC), resulted were affected by the simultaneous integrated boost on LPLN with a survival rate of 84.7%, 79.5%, 84.1%, and 92%, respectively, in the entire population. From the comparison of the two groups, there was a statistical significance towards the RT boost group with a p < 0.006, 0.030, 0.042, 0.026, respectively. Conclusions: Concomitant radiotherapy boost on positive LPLN has shown to be beneficial on the survival outcomes (OS, DFS, MFR, and LC) in patients with LARC and LPLN. This analysis demonstrates that a higher dose of radiotherapy on positive pelvic lymph nodes led not only to a higher local control but also to a better survival rate. These results, if validated by future prospective studies, can bring a valid alternative to the surgery dissection without the important side effects and permanent disabilities observed during the years.

Identifiants

pubmed: 35406415
pii: cancers14071643
doi: 10.3390/cancers14071643
pmc: PMC8996944
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Mol Clin Oncol. 2016 Jun;4(6):994-1002
pubmed: 27313860
Br J Hosp Med (Lond). 2013 Jul;74(7):377-80
pubmed: 24159637
Cancer Manag Res. 2021 Jan 22;13:537-546
pubmed: 33519233
Surgery. 2021 May;169(5):1005-1015
pubmed: 33317903
Clin Colon Rectal Surg. 2017 Nov;30(5):324-332
pubmed: 29184467
J Surg Oncol. 2015 Mar 15;111(4):459-64
pubmed: 25559888
Radiat Oncol. 2011 Jun 08;6:63
pubmed: 21651775
Oncology. 2019;96(1):33-43
pubmed: 30212816
J Am Coll Surg. 1997 May;184(5):475-80
pubmed: 9145067
J Gastrointest Oncol. 2021 Apr;12(2):496-506
pubmed: 34012643
Colorectal Dis. 2013 Jul;15(7):781-4
pubmed: 23701484
J Clin Oncol. 2019 Jan 1;37(1):33-43
pubmed: 30403572
Ann Surg Oncol. 2015 Dec;22 Suppl 3:S614-20
pubmed: 25896145
Int J Colorectal Dis. 2018 Sep;33(9):1159-1168
pubmed: 29978363
Dis Colon Rectum. 2006 Nov;49(11):1663-72
pubmed: 17041749
Ann Surg Oncol. 2016 Apr;23(4):1187-94
pubmed: 26671038
J Natl Cancer Inst. 2001 Apr 18;93(8):583-96
pubmed: 11309435
Radiol Oncol. 2018 Feb 08;52(1):23-29
pubmed: 29520202
J Natl Compr Canc Netw. 2018 Jul;16(7):874-901
pubmed: 30006429
Ann Surg Oncol. 2016 Aug;23(Suppl 4):552-558
pubmed: 27393567
Radiat Oncol. 2010 Feb 26;5:17
pubmed: 20187944
Int J Radiat Oncol Biol Phys. 2006 Jun 1;65(2):445-51
pubmed: 16690432
Ann Surg. 2009 Feb;249(2):229-35
pubmed: 19212175
Radiat Oncol. 2014 Dec 11;9:280
pubmed: 25498196
Br J Surg. 2006 Oct;93(10):1215-23
pubmed: 16983741
Front Oncol. 2021 Feb 22;10:627572
pubmed: 33692945
Lancet Oncol. 2012 Jun;13(6):616-21
pubmed: 22591948
Eur J Surg Oncol. 2016 Dec;42(12):1851-1858
pubmed: 27519616
World J Gastrointest Oncol. 2012 Dec 15;4(12):230-7
pubmed: 23443049
Lancet Oncol. 2009 Nov;10(11):1053-62
pubmed: 19767239
Anticancer Res. 2007 Sep-Oct;27(5B):3529-33
pubmed: 17972513
Ann Oncol. 2019 Aug 1;30(8):1298-1303
pubmed: 31192355
Radiother Oncol. 2014 Jan;110(1):155-9
pubmed: 24239243
Int J Clin Oncol. 2018 Feb;23(1):1-34
pubmed: 28349281
Cochrane Database Syst Rev. 2012 Mar 14;(3):CD004078
pubmed: 22419291
Dis Colon Rectum. 2014 Mar;57(3):399-402
pubmed: 24509468
Eur Radiol. 2018 Apr;28(4):1465-1475
pubmed: 29043428
Int J Radiat Oncol Biol Phys. 2018 Mar 1;100(3):730-737
pubmed: 29248169

Auteurs

Elisa Meldolesi (E)

Department of Radiology, Radiation Oncology and Hematology, Catholic University of the Sacred Heart, Agostino Gemelli University Hospital Foundation IRCCS, 00168 Roma, Italy.

Giuditta Chiloiro (G)

Department of Radiology, Radiation Oncology and Hematology, Catholic University of the Sacred Heart, Agostino Gemelli University Hospital Foundation IRCCS, 00168 Roma, Italy.

Roberta Giannini (R)

Department of Radiology, Radiation Oncology and Hematology, Catholic University of the Sacred Heart, Agostino Gemelli University Hospital Foundation IRCCS, 00168 Roma, Italy.

Roberta Menghi (R)

Digestive Surgery Unit, Catholic University of the Sacred Heart, Agostino Gemelli University Hospital Foundation IRCCS, 00168 Rome, Italy.

Roberto Persiani (R)

Digestive Surgery Unit, Catholic University of the Sacred Heart, Agostino Gemelli University Hospital Foundation IRCCS, 00168 Rome, Italy.

Barbara Corvari (B)

Department of Radiology, Radiation Oncology and Hematology, Catholic University of the Sacred Heart, Agostino Gemelli University Hospital Foundation IRCCS, 00168 Roma, Italy.

Claudio Coco (C)

Digestive Surgery Unit, Catholic University of the Sacred Heart, Agostino Gemelli University Hospital Foundation IRCCS, 00168 Rome, Italy.

Stefania Manfrida (S)

Department of Radiology, Radiation Oncology and Hematology, Catholic University of the Sacred Heart, Agostino Gemelli University Hospital Foundation IRCCS, 00168 Roma, Italy.

Carlo Ratto (C)

Digestive Surgery Unit, Catholic University of the Sacred Heart, Agostino Gemelli University Hospital Foundation IRCCS, 00168 Rome, Italy.

Viola De Luca (V)

Department of Radiology, Radiation Oncology and Hematology, Catholic University of the Sacred Heart, Agostino Gemelli University Hospital Foundation IRCCS, 00168 Roma, Italy.

Luigi Sofo (L)

Digestive Surgery Unit, Catholic University of the Sacred Heart, Agostino Gemelli University Hospital Foundation IRCCS, 00168 Rome, Italy.

Sara Reina (S)

Department of Radiology, Radiation Oncology and Hematology, Catholic University of the Sacred Heart, Agostino Gemelli University Hospital Foundation IRCCS, 00168 Roma, Italy.

Antonio Crucitti (A)

Digestive Surgery Unit, Catholic University of the Sacred Heart, Agostino Gemelli University Hospital Foundation IRCCS, 00168 Rome, Italy.

Valeria Masiello (V)

Department of Radiology, Radiation Oncology and Hematology, Catholic University of the Sacred Heart, Agostino Gemelli University Hospital Foundation IRCCS, 00168 Roma, Italy.

Nicola Dinapoli (N)

Department of Radiology, Radiation Oncology and Hematology, Catholic University of the Sacred Heart, Agostino Gemelli University Hospital Foundation IRCCS, 00168 Roma, Italy.

Vincenzo Valentini (V)

Department of Radiology, Radiation Oncology and Hematology, Catholic University of the Sacred Heart, Agostino Gemelli University Hospital Foundation IRCCS, 00168 Roma, Italy.

Maria Antonietta Gambacorta (MA)

Department of Radiology, Radiation Oncology and Hematology, Catholic University of the Sacred Heart, Agostino Gemelli University Hospital Foundation IRCCS, 00168 Roma, Italy.

Classifications MeSH